
Quarterly report 2023-Q3
added 11-14-2023
Bellerophon Therapeutics Net Debt 2011-2026 | BLPH
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Bellerophon Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -23.8 M | -45.9 M | -7.56 M | -16.6 M | -28.8 M | -14.5 M | -6.26 M | -16.8 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.26 M | -45.9 M | -20 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Adagene
ADAG
|
-71 M | $ 2.83 | -2.75 % | $ 159 M | ||
|
Biogen
BIIB
|
4.01 B | $ 177.27 | 0.62 % | $ 25.8 B | ||
|
ANI Pharmaceuticals
ANIP
|
166 M | $ 81.19 | -0.98 % | $ 1.57 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Amgen
AMGN
|
44.7 B | $ 339.82 | -0.91 % | $ 182 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 114.47 | -1.97 % | $ 27.2 B | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 9.65 | -0.16 % | $ 1.52 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.56 | -0.78 % | $ 16.1 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.23 | -0.92 % | $ 7.77 B | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
CASI Pharmaceuticals
CASI
|
-36.5 M | $ 0.99 | - | $ 135 M | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 10.0 | -1.43 % | $ 658 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Cerus Corporation
CERS
|
-6.33 M | $ 2.3 | -1.08 % | $ 424 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Cellectis S.A.
CLLS
|
-206 M | $ 3.81 | -4.51 % | $ 116 M | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Beam Therapeutics
BEAM
|
-121 M | $ 28.26 | -3.52 % | $ 2.33 B | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 223.79 | -0.07 % | $ 5 B | ||
|
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | ||
|
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 68.89 | -0.33 % | $ 9.21 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
-514 M | $ 24.53 | -0.2 % | $ 2.91 B | ||
|
Cardiff Oncology
CRDF
|
-49.9 M | $ 1.68 | 3.75 % | $ 80.1 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 4.03 | -1.71 % | $ 8.77 B | ||
|
Amneal Pharmaceuticals
AMRX
|
2.28 B | $ 13.77 | -2.45 % | $ 4.25 B | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B |